NASDAQ:BTAI BioXcel Therapeutics - BTAI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.66 -0.35 (-1.09%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$31.54▼$32.4850-Day Range$14.49▼$32.7352-Week Range$8.80▼$32.96Volume192,193 shsAverage Volume359,689 shsMarket Capitalization$887.18 millionP/E RatioN/ADividend YieldN/APrice Target$51.78 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability BioXcel Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside67.1% Upside$52.89 Price TargetShort InterestBearish12.20% of Float Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews Sentiment0.59Based on 9 Articles This WeekInsider TradingSelling Shares$3.07 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.37) to ($5.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.63 out of 5 starsMedical Sector128th out of 1,055 stocksPharmaceutical Preparations Industry50th out of 519 stocks 4.4 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.89, BioXcel Therapeutics has a forecasted upside of 67.1% from its current price of $31.66.Amount of Analyst CoverageBioXcel Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.20% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 3.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 3.1 News and Social Media Coverage News SentimentBioXcel Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for BioXcel Therapeutics this week, compared to 2 articles on an average week.Search Interest23 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows10 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,073,310.00 in company stock.Percentage Held by Insiders37.00% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.35% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to decrease in the coming year, from ($5.37) to ($5.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioXcel Therapeutics has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioXcel Therapeutics (NASDAQ:BTAI) StockBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Read More Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Stock News HeadlinesJanuary 27, 2023 | finance.yahoo.comBTAI: Multiple Catalysts Ahead in 2023January 27, 2023 | americanbankingnews.comFrank Yocca Sells 50,000 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) StockJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 25, 2023 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Average Rating of "Moderate Buy" from BrokeragesJanuary 24, 2023 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 10.1% in DecemberJanuary 24, 2023 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest UpdateJanuary 19, 2023 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Trading Down 5.6%January 13, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)January 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 11, 2023 | markets.businessinsider.comBioXcel Announces Promising Data From Phase 2 Trial Of BXCL701 Combination In Rare Prostate CancerJanuary 11, 2023 | finance.yahoo.comBioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate CancerDecember 27, 2022 | finance.yahoo.comA great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happyDecember 22, 2022 | finance.yahoo.comBioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comBioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 19, 2022 | finance.yahoo.comBioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s DiseaseDecember 15, 2022 | finance.yahoo.comWhy BioXCel Therapeutics Stock Jumped This WeekDecember 3, 2022 | finance.yahoo.comWhy BioXcel Therapeutics Stock Triumphed This WeekDecember 1, 2022 | finance.yahoo.comBioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap ConferenceNovember 30, 2022 | finance.yahoo.comBioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or SchizophreniaNovember 18, 2022 | markets.businessinsider.comCramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'November 14, 2022 | finance.yahoo.comBTAI: Positive Early Metrics for IGALMI™ Launch…November 14, 2022 | finance.yahoo.comBioXcel Therapeutics to Present at Two Upcoming Investor ConferencesNovember 10, 2022 | seekingalpha.comBioXcel stock soars 17% as lead drug Igalmi starts to bring in revenueNovember 10, 2022 | finance.yahoo.comBioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational HighlightsOctober 27, 2022 | finance.yahoo.comBioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022October 5, 2022 | finance.yahoo.comBioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022September 14, 2022 | finance.yahoo.comBioXcel Therapeutics, Inc. (BTAI)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Company Calendar Last Earnings11/10/2022Today1/27/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees89Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.89 High Stock Price Forecast$80.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+63.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,930,000.00 Net MarginsN/A Pretax Margin-100,052.56% Return on Equity-77.56% Return on Assets-58.11% Debt Debt-to-Equity Ratio0.72 Current Ratio10.34 Quick Ratio10.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.92 per share Price / Book4.00Miscellaneous Outstanding Shares28,022,000Free Float17,654,000Market Cap$887.18 million OptionableNot Optionable Beta1.16 Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, Pres, & Director Comp: $1.41MDr. Frank D. Yocca Ph.D. (Age 67)Sr. VP & Chief Scientific Officer Comp: $452.58kMr. Javier Rodriguez (Age 51)Sr. VP, Chief Legal Officer & Corp. Sec. Comp: $470.53kDr. Krishnan Nandabalan Ph.D. (Age 60)Chief Digital Officer ?& Director Comp: $150kMr. Richard I. Steinhart MBA (Age 66)Sr. VP & CFO Ms. Mary ColemanVP of Investment RelationsDr. Iris Francesconi Ph.D.Sr. VP of Marketing, Market Research & Commercial AssessmentsDr. Vincent J. O'Neill M.D. (Age 54)B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer Dr. Cedric BurgVP and Head of Global Clinical Operations & Project ManagementDr. Chetan D. Lathia Ph.D.Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsMore ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMInnovivaNASDAQ:INVAPharming GroupNASDAQ:PHARJanux TherapeuticsNASDAQ:JANXRAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsArtemis Investment Management LLPSold 40,805 shares on 1/25/2023Ownership: 4.760%DAVENPORT & Co LLCBought 48,560 shares on 1/20/2023Ownership: 0.561%Frank YoccaSold 50,000 sharesTotal: $1.50 M ($30.00/share)Hennion & Walsh Asset Management Inc.Bought 4,954 shares on 1/12/2023Ownership: 0.140%Krishnan NandabalanSold 25,889 sharesTotal: $578,360.26 ($22.34/share)View All Insider TransactionsView All Institutional Transactions BTAI Stock - Frequently Asked Questions Should I buy or sell BioXcel Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BTAI shares. View BTAI analyst ratings or view top-rated stocks. What is BioXcel Therapeutics' stock price forecast for 2023? 8 analysts have issued twelve-month price objectives for BioXcel Therapeutics' shares. Their BTAI share price forecasts range from $24.00 to $80.00. On average, they predict the company's stock price to reach $52.89 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts. How have BTAI shares performed in 2023? BioXcel Therapeutics' stock was trading at $21.48 at the beginning of the year. Since then, BTAI stock has increased by 47.4% and is now trading at $31.66. View the best growth stocks for 2023 here. When is BioXcel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our BTAI earnings forecast. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Thursday, November, 10th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by $0.15. The firm earned $0.14 million during the quarter, compared to analysts' expectations of $3.05 million. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). When did BioXcel Therapeutics IPO? (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is BioXcel Therapeutics' stock symbol? BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI." Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (4.76%), DAVENPORT & Co LLC (0.56%) and Hennion & Walsh Asset Management Inc. (0.14%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Krishnan Nandabalan, Vimal Mehta and Vincent O'neill. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioXcel Therapeutics' stock price today? One share of BTAI stock can currently be purchased for approximately $31.66. How much money does BioXcel Therapeutics make? BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $887.18 million. The company earns $-106,930,000.00 in net income (profit) each year or ($4.89) on an earnings per share basis. How can I contact BioXcel Therapeutics? BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com. This page (NASDAQ:BTAI) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.